- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03729869
Impact of Progesterone on Stress Reactivity and Cannabis Use
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Aimee McRae-Clark, PharmD
- Phone Number: 843-792-5216
- Email: mcraeal@musc.edu
Study Contact Backup
- Name: Lisa Nunn, MS
- Phone Number: 843-792-0476
- Email: jenkinli@musc.edu
Study Locations
-
-
South Carolina
-
Charleston, South Carolina, United States, 29403
- Medical University of South Carolina
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
1. Able to provide informed consent and function at an intellectual level sufficient to allow accurate completion of all assessment instruments.
2. Meet DSM-5 criteria for moderate or severe cannabis use disorder (within the past three months) and report using cannabis at least five times weekly over the past month. While individuals may also meet criteria for mild use disorders of other substances, they must identify cannabis as their primary substance of abuse and must not meet criteria for any other moderate or severe substance use disorder (except tobacco) within the last 60 days.
3. Age 18-45. 4. For women, regular menses (every 25-35 days). 5. Consent to remain abstinent from alcohol for 12 hours prior to study visits, and all other drugs other than cannabis or nicotine for the duration of the study.
6. Women of childbearing potential must agree to utilize an effective means of birth control.
7. Must consent to random assignment.
Exclusion Criteria:
. Women who are pregnant, nursing or of childbearing potential and not practicing an effective means of birth control.
2. Women who are amennorheic or using progesterone-based contraceptives. 3. Evidence or history of major medical illnesses, including liver diseases, abnormal vaginal bleeding, suspected or known malignancy, thrombophlebitis, deep vein thrombosis, pulmonary embolus, clotting or bleeding disorders, heart disease, diabetes, history of stroke or other medical conditions that the investigator deems as contraindicated for the individual to be in the study.
4. History of or current psychotic disorder or bipolar affective disorder. 5. Current suicidal or homicidal ideation/risk. 6. Known allergy to progesterone or peanuts (vehicle for micronized progesterone).
7. Unwilling or unable to maintain abstinence from alcohol 12 hours prior to study visits and all other drugs other than cannabis or nicotine for the duration of the study.
8. Meet DSM-5 criteria for moderate or severe substance use disorder (other than nicotine or cannabis) within the past 60 days.
9. Unable to comply with study procedures or pose threat to study staff.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Progesterone Males
35 men will take 400 mg of progesterone a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
|
200 mg of exogenous progesterone twice a day
Other Names:
|
Placebo Comparator: Placebo Males
35 men will take placebo twice a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
|
One dose of matched placebo twice a day.
|
Experimental: Progesterone Female
35 women will take 200 mg of progesterone twice a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
|
200 mg of exogenous progesterone twice a day
Other Names:
|
Placebo Comparator: Placebo Females
35 women will take placebo twice a day for 7 days and will complete a stress and marijuana cue reactivity task following the final dose.
|
One dose of matched placebo twice a day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cannabis Craving
Time Frame: Immediately post stress/cue task.
|
Subjects will rate marijuana craving on a 0-7 Likert scale where 0 is Not at All and 7 is extremely.
|
Immediately post stress/cue task.
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00081360
- 2U54DA016511-16 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cannabis Use
-
Centre hospitalier de l'Université de Montréal...RecruitingCannabis | Cannabis Dependence | Cannabis Use | Cannabis Smoking | Cannabis Use, UnspecifiedCanada
-
The University of Tennessee, KnoxvilleColorado State UniversityActive, not recruitingCannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingCannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereUnited States
-
Elias DakwarRecruitingAddiction | Cannabis Dependence | Cannabis Use | Substance Abuse | Cannabis Abuse | Cannabis Use DisorderUnited States
-
Monash UniversityTurning PointCompletedCannabis Use Disorder, Moderate | Cannabis Use Disorder, SevereAustralia
-
Oregon Research InstituteCompletedCannabis Use Disorder, Mild | Cannabis Use Disorder, ModerateUnited States
-
University of California, San FranciscoNational Institute on Drug Abuse (NIDA); National Institutes of Health (NIH); Food and Drug Administration (FDA)Not yet recruitingTobacco Use | Cannabis | Cannabis Use | Vaping | THC | Cannabis SmokingUnited States
-
Medical University of South CarolinaNational Institute on Drug Abuse (NIDA)RecruitingBipolar Disorder | Cannabis Use | Bipolar I Disorder | Cannabis Use Disorder, Mild | Cannabis Use Disorder, Moderate | Cannabis Use Disorder, Severe | Bipolar II Disorder | Schizoaffective Disorder, Bipolar TypeUnited States
-
Hartford HospitalYale UniversityNot yet recruitingMarijuana Use | Cannabis Use | Cannabis Intoxication
-
McMaster UniversityCenter for Medicinal Cannabis ResearchNot yet recruitingCannabis Use Disorder, Moderate | Cannabis Use Disorder, Severe
Clinical Trials on Progesterone
-
Brigham and Women's HospitalWithdrawnInfertilityUnited States
-
Aswan University HospitalUnknownTwin; Pregnancy, Affecting Fetus or NewbornEgypt
-
Shady Grove Fertility Reproductive Science CenterFerring PharmaceuticalsCompleted
-
Heilongjiang University of Chinese MedicineRecruitingThreatened MiscarriageChina
-
IBSA Institut Biochimique SACompleted
-
Institut Universitari DexeusFundación Santiago Dexeus Font; Dexeus Clinic WomanCompletedInfertility | Frozen Embryo Transfer | Pregnancy Outcome | Progesterone | Euploid Embryo Transfer | Artificial Cycle | Ongoing PregnancySpain
-
University of British ColumbiaCompletedPerimenopause | Menstrual CrampsCanada
-
Thomas Jefferson UniversityOhio State University; George Washington University; Baystate Medical Center; Vriginia...CompletedPremature BirthUnited States
-
Instituto BernabeuCompleted
-
Instituto Valenciano de Infertilidad, IVI VALENCIACompleted